Product
CIN-107
Aliases
baxdrostat
8 clinical trials
5 indications
Indication
HypertensionIndication
Chronic Kidney DiseaseIndication
Primary AldosteronismIndication
HyperaldosteronismIndication
Resistant HypertensionClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-03-05
Clinical trial
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary AldosteronismStatus: Active (not recruiting), Estimated PCD: 2024-10-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (rHTN)Status: Completed, Estimated PCD: 2022-06-14
Clinical trial
A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CIN-107 Following Multiple Oral Doses in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-04-03
Clinical trial
A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled HypertensionStatus: Completed, Estimated PCD: 2022-09-13
Clinical trial
An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107Status: Completed, Estimated PCD: 2023-11-07
Clinical trial
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionStatus: Completed, Estimated PCD: 2021-04-30
Clinical trial
A Randomized, Open-Label, Two-Period, Crossover Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-12-12